Main public logs
Jump to navigation
Jump to search
Combined display of all available logs of wikidoc. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).
- 23:02, 8 June 2024 Kosar Doraghi talk contribs created page Xolremdi (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=mavorixafor |aOrAn=a |drugClass=CXC chemokine receptor 4 (CXCR4) antagonist |indicationType=treatment |indication=patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. |hasBlackBoxWarning=Yes |adverseReactions=thrombocytopenia, pityr...")
- 22:52, 8 June 2024 Kosar Doraghi talk contribs created page File:IMG 1240.jpeg
- 22:52, 8 June 2024 Kosar Doraghi talk contribs uploaded File:IMG 1240.jpeg
- 22:50, 8 June 2024 Kosar Doraghi talk contribs created page File:IMG 1239.jpeg
- 22:50, 8 June 2024 Kosar Doraghi talk contribs uploaded File:IMG 1239.jpeg
- 22:49, 8 June 2024 Kosar Doraghi talk contribs created page File:IMG 1238.jpeg
- 22:49, 8 June 2024 Kosar Doraghi talk contribs uploaded File:IMG 1238.jpeg
- 23:19, 2 June 2024 Rithish Nimmagadda talk contribs created page Iptacopa (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=iptacopa |aOrAn=a |drugClass=complement factor B inhibitor. |indicationType=treatment |indication=adults with paroxysmal nocturnal hemoglobinuria (PNH). |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions in adults with PNH (incidence ≥10%) were headache, nasopharyngitis, diarrhea, abdominal pain, bacterial infection, viral infection, nausea, and rash. |blackBoxWarningTitle=Serious Infecti...")
- 02:54, 2 June 2024 Kosar Doraghi talk contribs created page File:IMG 1235.jpeg
- 02:54, 2 June 2024 Kosar Doraghi talk contribs uploaded File:IMG 1235.jpeg
- 02:53, 2 June 2024 Kosar Doraghi talk contribs created page File:IMG 1234.jpeg
- 02:53, 2 June 2024 Kosar Doraghi talk contribs uploaded File:IMG 1234.jpeg
- 02:52, 2 June 2024 Kosar Doraghi talk contribs created page File:IMG 1231.jpeg
- 02:52, 2 June 2024 Kosar Doraghi talk contribs uploaded File:IMG 1231.jpeg
- 02:51, 2 June 2024 Kosar Doraghi talk contribs created page File:IMG 1232.jpeg
- 02:51, 2 June 2024 Kosar Doraghi talk contribs uploaded File:IMG 1232.jpeg
- 02:49, 2 June 2024 Kosar Doraghi talk contribs created page File:IMG 1230.jpeg
- 02:49, 2 June 2024 Kosar Doraghi talk contribs uploaded File:IMG 1230.jpeg
- 02:49, 2 June 2024 Kosar Doraghi talk contribs created page File:IMG 1227.jpeg
- 02:49, 2 June 2024 Kosar Doraghi talk contribs uploaded File:IMG 1227.jpeg
- 02:48, 2 June 2024 Kosar Doraghi talk contribs created page File:IMG 1236.jpeg
- 02:48, 2 June 2024 Kosar Doraghi talk contribs uploaded File:IMG 1236.jpeg
- 02:46, 2 June 2024 Kosar Doraghi talk contribs created page File:IMG 1237.jpeg
- 02:46, 2 June 2024 Kosar Doraghi talk contribs uploaded File:IMG 1237.jpeg
- 02:41, 2 June 2024 Kosar Doraghi talk contribs created page File:IMG 1226.jpeg
- 02:41, 2 June 2024 Kosar Doraghi talk contribs uploaded File:IMG 1226.jpeg
- 03:20, 1 June 2024 Kosar Doraghi talk contribs created page WINREVAIR (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=sotatercept-csrk |aOrAn=an |drugClass=activin signaling inhibitor |indicationType=treatment |indication=adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events |hasBlackBoxWarning=Yes |adverseReactions=headache, epistaxis, rash, telangiect...")
- 23:42, 27 May 2024 Jonathan Reyes talk contribs created page Evinacumab-dgnb (Created page with "{{DrugProjectFormSinglePage |authorTag={{JR}} |genericName=evinacumab-dgnb |aOrAn=an |drugClass=angiopoietin-like 3 (ANGPTL3) inhibitor |indicationType=treatment |indication=Evanicumab-dgnb is an angiopoietin-like 3 (ANGPTL3) inhibitor that is FDA approved for the treatment of an adjunct to other low-density lipoproteincholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholestero...")
- 22:59, 27 May 2024 Jonathan Reyes talk contribs created page Template:JR (Created page with "Jonathan Reyes, M.D.[jona3098reyes@gmail.com]")
- 14:40, 23 May 2024 Muhammad Waleed talk contribs created page Glofitamab-gxbm (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=glofitamab. |aOrAn=a |drugClass=bispecific antibodies |indicationType=treatment |indication=COLUMVI (glofitamab) has been approved by the FDA for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or large B-cell lymphoma arising from follicular lymphoma aft...")
- 12:43, 23 May 2024 Muhammad Waleed talk contribs created page Rozanolixizumab-noli (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Rozanolixizumab-noli (Rystiggo) |aOrAn=a |drugClass=Neonatal Fc receptor blocker |indicationType=treatment |indication=Rystiggo is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. |adverseReac...")
- 02:00, 23 May 2024 Kosar Doraghi talk contribs created page Aprocitentan (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar.Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=aprocitentan |aOrAn=an |drugClass=endothelin receptor antagonist |indicationType=treatment |indication=hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs |hasBlackBoxWarning=Yes |adverseReactions=edema/fluid retention and anemia |blackBoxWarningTitle=W...")
- 01:49, 23 May 2024 Kosar Doraghi talk contribs created page File:IMG 1225.jpeg
- 01:49, 23 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1225.jpeg
- 01:28, 23 May 2024 Kosar Doraghi talk contribs created page File:IMG 1224.jpeg
- 01:28, 23 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1224.jpeg
- 01:28, 23 May 2024 Kosar Doraghi talk contribs created page File:IMG 1223.jpeg
- 01:28, 23 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1223.jpeg
- 23:53, 22 May 2024 Alberto Castro Molina talk contribs created page File:Captura de Pantalla 2024-05-18 a la(s) 9.33.11 p.m..png
- 23:53, 22 May 2024 Alberto Castro Molina talk contribs uploaded File:Captura de Pantalla 2024-05-18 a la(s) 9.33.11 p.m..png
- 21:25, 21 May 2024 Alen Antony talk contribs created page Pegunigalsidase alfa-iwxj (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=pegunigalsidase alfa-iwxj |indicationType=treatment |indication=Fabry's disease in adults |hasBlackBoxWarning=Yes |adverseReactions=infusion-associated reactions, nasopharyngitis, headache, diarrhea, fatigue, nausea, back pain, pain in extremity, and sinusitis. |blackBoxWarningTitle=HYPERSENSITIVITY REACTIONS including Anaphylaxis |blackBoxWarningBody=Patients may experience hypersensitivity reaction including a...")
- 18:33, 21 May 2024 Rithish Nimmagadda talk contribs created page Vonoprazan, amoxicillin, and clarithromycin (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=vonoprazan, amoxicillin, and clarithromycin |aOrAn=a |drugClass=Potassium-competitive acid blocker |indicationType=treatment |indication=- erosive esophagitis (all grades) and relief of heartburn associated with erosive esophagitis in adults. ,Helicobacter pylori Infection |adverseReactions=-Common adverse reactions (≥2%) with vonoprazan when used for healing of erosive esophagitis: gastritis, diarrhea, abdom...")
- 16:59, 21 May 2024 Rithish Nimmagadda talk contribs created page Pirtobrutinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=pirtobrutinib |aOrAn=an |drugClass=noncovalent (reversible) inhibitor of Bruton's tyrosine kinase (BTK). |indicationType=treatment |indication=elapsed or refractory MCL in adults who have received at least 2 lines of prior systemic therapy, including a BTK inhibitor; designated an orphan drug by FDA for treatment of MCL and also in treatment of CLL or SLL in adults who have received at least 2 prior lines of th...")
- 00:09, 21 May 2024 Rithish Nimmagadda talk contribs created page Elacestrant (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=elacestrant |aOrAn=an |drugClass=estrogen receptor antagonist |indicationType=treatment |indication=estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer that has progressed following ≥1 line of endocrine-based therapy in postmenopausal women or adult men. |fdaLIADAdult=Dosage of elacestrant hydro...")
- 23:07, 20 May 2024 Rithish Nimmagadda talk contribs created page Velmanase alfa-tycv (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=velmanase alfa-tycv |aOrAn=an |drugClass=recombinant preparation of human lysosomal alpha-mannosidase |indicationType=treatment |indication=non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients |adverseReactions=Most common adverse reactions (incidence >20%) are hypersensitivity reactions (including anaphylaxis), nasopharyngitis, pyrexia, headache, and arthralgia. |blac...")
- 20:31, 20 May 2024 Rithish Nimmagadda talk contribs created page Retifanlimab-dlwr (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=retifanlimab-dlwr |aOrAn=an |indicationType=treatment |indication=adults with metastatic or recurrent locally advanced Merkel cell carcinoma . Indication approved under accelerated approval based on tumor response rate and duration of response; continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. |adverseReactions=Adverse effects (≥10%): fatigue...")
- 20:18, 20 May 2024 Rithish Nimmagadda talk contribs created page Tofersen (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=tofersen |aOrAn=an |drugClass=antisense oligonucleotide |indicationType=treatment |indication=amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. |adverseReactions=he most common adverse reactions (≥ 10% of patients treated with tofersen and greater than placebo) were pain, fatigue, arthralgia, increased CSF white blood cell, and myalgia. |fdaLIADAdult=...")
- 16:01, 18 May 2024 Rithish Nimmagadda talk contribs created page Ritlecitinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=ritlecitinib |aOrAn=a |drugClass=janus kinase 3 (JAK3) inhibitor and also an inhibitor of the tyrosine kinase |indicationType=treatment |indication=severe alopecia areata in adults and adolescents 12 years of age and older |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (incidence ≥1%) are headache, diarrhea, acne, rash, urticaria, folliculitis, pyrexia, atopic dermatitis, dizziness, i...")
- 17:21, 17 May 2024 Rithish Nimmagadda talk contribs created page Quizartinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=quizartinib |aOrAn=a |drugClass=a kinase inhibitor |indicationType=treatment |indication=adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test. |hasBlackBoxWarning=Yes |adverseReactions=The most common (>20%) adverse reactions, including laboratory abnormalities, are decreased lymphocytes, decreased potassium,...")
- 16:40, 17 May 2024 Rithish Nimmagadda talk contribs created page Lotilaner (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=lotilaner |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA)-gated chloride channel inhibitor |indication=ectoparasiticide (anti-parasitic) indicated for the treatment of Demodex blepharitis |adverseReactions=The most common adverse reaction was instillation site stinging and burning |fdaLIADAdult=still one drop of lotilaner in each eye twice daily (approximately 12 hours apart) for 6 weeks. |fdaLIADPed=Safety...")
_9.33.11_p.m..png){kind=link}